Literature DB >> 12903546

[Peritoneal mesothelioma: results of a complicated and aggressive procedure incorporating peritonectomy and intraperitoneal hyperthermic chemotherapy, and prospects derived from bench-to-bedside research].

M Deraco1, S Kusamura, D Baratti, P Casali, N Zaffaroni.   

Abstract

Peritoneal mesothelioma (PM) is a rare primary peritoneal tumor conditioning a very poor quality of life and prognosis. Twenty eight patients (11 men and 17 women) with PM were referred to National Cancer Institute of Milan and submitted to 29 consecutive procedures of peritonectomy and intra peritoneal hyperthermic perfusion (IPHP). Five years overall survival, disease free survival and progression free survival have been 70, 63 and 51%, respectively. Morbidity and toxicity were 14 and 21% respectively. No mortality has been observed peritonectomy associated with IPHP is an effective approach to cure patients PM.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12903546

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916            Impact factor:   2.098


  4 in total

1.  Combination chemotherapy with cisplatin and gemcitabine in malignant peritoneal mesothelioma.

Authors:  Satoshi Tanida; Hiromi Kataoka; Eiji Kubota; Yoshinori Mori; Makoto Sasaki; Naotaka Ogasawara; Tsuneya Wada; Tsutomu Mizoshita; Takaya Shimura; Kenji Murakami; Takashi Mizushima; Yoshikazu Hirata; Yasuyuki Okamoto; Motoshi Mabuchi; Masahide Ebi; Mamoru Tanaka; Takeshi Kamiya; Satoru Takahashi; Takashi Joh
Journal:  Int J Clin Oncol       Date:  2009-07-11       Impact factor: 3.402

Review 2.  Peritoneal mesothelioma: a review.

Authors:  Alessio Bridda; Ilaria Padoan; Roberto Mencarelli; Mauro Frego
Journal:  MedGenMed       Date:  2007-05-10

Review 3.  Advances in the management of peritoneal mesothelioma.

Authors:  Ali Raza; Wei-Ching Huang; Kazuaki Takabe
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

Review 4.  Malignant mesothelioma.

Authors:  Ishtiaq Ahmed; Salman Ahmed Tipu; Sundas Ishtiaq
Journal:  Pak J Med Sci       Date:  2013-11       Impact factor: 1.088

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.